The explanations behind the wide spreadability of coronavirus sickness (COVID-19) are not known properly in this world. Several clinical investigations have indicated that the BCG antibody impacts on the immune system and human sicknesses which take part in the host system to such an extent that numerous types of viral diseases are extensively diminished or reduced. Subsequently, it was also observed in different studies that the recurrence and seriousness of numerous microbial or viral diseases, including COVID-19, will be lower in few countries where BCG Immunization programs are carried out. Few clinical investigations proposed by the epidemiological data have shown that the BCG antibody has a valuable impact in the treatment of COVID-19. So the BCG immunization may be found valuable in the coming months, particularly in the countries, where mass BCG immunization is done. Further thorough BCG immunization clinical trial is required to establish the above findings and its clinical significance. In future, this investigation will concentrate on the BCG vaccine and it may forestall the event of SARS-CoV-2 contamination and its succession in the large population.
[http://dx.doi.org/10.1111/j.1464-410X.2012.11390.x] [PMID: 23253618]
[http://dx.doi.org/10.4103/0378-6323.193623] [PMID: 27852999]
[http://dx.doi.org/10.1016/S1473-3099(18)30786-2] [PMID: 31006605]
[http://dx.doi.org/10.1016/j.jtbi.2019.05.003] [PMID: 31059716]
[http://dx.doi.org/10.1111/j.1346-8138.2006.00128.x] [PMID: 16923135]